— Matinas BioPharma (NYSE: MTNB) reported loss of $0.04 per share in the fourth quarter of 2019, vs $0.03 per share loss expected.
— Initiated ENHANCE-IT study of MAT9001 against Vascepa. Topline data expected Q4 2020.
— Cash, cash equivalents and marketable securities at December 31, 2019 were approx. $27.8 million, compared to $12.4 million a year ago.
— MTNB shares ended down 2.75% in its last trading session on Friday.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Key highlights from Autodesk (ADSK) Q4 2021 earnings results
Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per
Infographic: Beyond Meat (BYND) reports wider Q4 loss; Revenue up 4%
Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus
Virgin Galactic stock tanks on delayed test flight
Virgin Galactic (NYSE: SPCE) reported fourth-quarter 2020 financial results after the regular market hours on Thursday. The space tourism company reported zero revenue in the fourth quarter, compared to $529,000
